Quarterly Report (10-q)

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 10-Q

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

OR

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 333-232839

 

 

BIO ESSENCE CORP.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

 

California

(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)

 

94-3349551
(IRS EMPLOYEE IDENTIFICATION NO.)

 

8 Studebaker Drive in Irvine, California 92618
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

[phone]
(ISSUER TELEPHONE NUMBER)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging Growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of the latest practicable date, the Company has 33,009,000 shares of its common stock issued and outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

		PAGE
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements
	Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021	1
	Statements of Operations for three months ended March 31, 2022 and 2021 (Unaudited)	2
	Statements of Cash Flows for three months ended March 31, 2022 and 2021 (Unaudited)	3
	Statements of Changes in Stockholders’ Equity for three months ended March 31, 2022 and 2021 (Unaudited)	4
	Notes to Financial Statements (Unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20
PART II		22
Item 1.	Legal Proceedings	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3.	Defaults Upon Senior Securities	22
Item 4.	Mine Safety Disclosures	22
Item 5.	Other Information	22
Item 6.	Exhibits	23
	Signatures	24

 

i

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

		AS OF MARCH 31,				AS OF DECEMBER 31,
		2022				2021
		(UNAUDITED)
ASSETS
CURRENT ASSETS
Cash and equivalents			225			$	303
Accounts receivable, net			72,184				16,820
Prepaid expenses			37,406				31,870
Advance to suppliers			10,636				-
Inventory, net			258,412				212,969
Total current assets			378,863				261,962
NONCURRENT ASSETS
Security deposit			41,841				41,841
Right-of-use assets, net			1,172,154				1,213,472
Property and equipment, net			186,171				180,909
Intangible assets, net			979				1,037
Total non-current assets			1,401,145				1,437,259
TOTAL ASSETS		$	1,780,008			$	1,699,221
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Bank overdraft		$	27,400			$	19,032
Accounts payable			114,698				62,583
Taxes payable			16,747				12,428
Accrued liabilities and other payables			105,851				77,109
Operating lease liabilities			161,341				161,732
Finance Lease Liability			4,672				-
Loan payables			11,311				11,814
Accrued interest on government loans			12,116				13,054
Government loans payable - current portion			4,469				4,427
Loan from shareholder			2,643,786				2,393,785
Total current liabilities			3,102,391				2,755,964
NONCURRENT LIABILITIES
Operating lease liabilities			1,081,973				1,122,902
Finance Lease Liability			11,405				-
Loan payables			34,964				37,918
Government loans payable			211,131				211,173
Total non-current liabilities			1,339,473				1,371,993
TOTAL LIABILITIES			4,441,864				4,127,957
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT
Preferred stock $0.0001 par value; authorized shares 10,000,000							-
Common stock $0.0001 par value; authorized shares 100,000,000; issued and outstanding shares 33,009,000 as of March 31, 2022 and December 31, 2021			3,301				3,301
Additional paid in capital			4,926,879				4,926,879
Accumulated deficit			(7,592,036	)			(7,358,916	)
TOTAL STOCKHOLDERS’ DEFICIT			(2,661,856	)			(2,428,736	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT		$	1,780,008			$	1,699,221

 

The accompanying notes are an integral part of these consolidated financial statements.

 

1

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

 

		THREE MONTHS ENDED MARCH 31,
		2022				2021
		(UNAUDITED)
Revenues
Sales of goods		$	181,579			$	212,028
Manufacture service revenue			124,835				-
Total revenues			306,414				212,028
Cost of revenues
Sales of goods			145,665				135,309
Cost of manufacture service			90,293				-
Total cost of revenues			235,958				135,309
Gross profit			70,456				76,719
Operating expenses
Selling			10,614				15,523
Bad debts			-				380
General and administrative			286,274				265,347
Total operating expenses			296,888				281,250
Loss from operations			(226,432	)			(204,531	)
Other income (expenses)
Interest expense			(5,160	)			(2,763	)
Financial expense			(1,568	)			(3,299	)
Other income			535				8,347
Other expenses			(495	)			(4,809	)
Other expenses, net			(6,688	)			(2,524	)
Loss before income tax			(233,120	)			(207,055	)
Income tax expense			-				3,300
Net loss		$	(233,120	)		$	(210,355	)
Basic and diluted weighted average shares outstanding			33,009,000				33,009,000
Basic and diluted net loss per share		$	(0.01	)		$	(0.01	)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

		THREE MONTHS ENDED MARCH 31,
		2022				2021
		(UNAUDITED)				(UNAUDITED)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(233,120	)		$	(210,355	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			10,874				8,515
Bad debts			-				380
Operating lease expense			57,717				57,311
Gain on disposal of fixed assets			-				(1,089	)
Increase (decrease) in assets: Changes in assets / liabilities:
Accounts receivable			(31,539	)			26,435
Prepaid expenses			(5,536	)			(1,218	)
Advance to suppliers			(10,636	)			2,548
Inventory			(45,442	)			(5,349	)
Accounts payable			28,291				926
Accrued liabilities and other payables			27,804				12,148
Taxes payable			4,319				6,767
Payment on lease liabilities			(57,207	)			(55,658	)
Net cash used in operating activities			(254,475	)			(158,639	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sales of fixed assets			-				2,700
Purchase of fixed assets			-				(9,537	)
Net cash used in investing activities			-				(6,837	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Bank overdraft			8,367				(28,982	)
Proceeds from government loans (SBA)			-				115,245
Repayment of loan payables			(3,970	)			-
Loan from shareholder			250,000				84,146
Net cash provided by financing activities			254,397				170,409
NET DECREASE IN CASH & EQUIVALENTS			(78	)			4,933
CASH & EQUIVALENTS, BEGINNING OF PERIOD			303				5,325
CASH & EQUIVALENTS, END OF PERIOD		$	225			$	10,258
Supplemental Cash Flow Data:
Income tax paid		$	-			$	3,300
Interest paid		$	6,098			$	2,763
Supplemental disclosures of non-cash financing activities:
fixed assets obtained in exchange for new financing lease liabilities		$	16,077			$	-

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3

 

 

BIO ESSENCE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

THREE MONTHS ENDED MARCH 31, 2022 AND 2022

(UNAUDITED)

 

		COMMON STOCK - SHARES				COMMON STOCK - AMOUNT				ADDITIONAL PAID IN CAPITAL				ACCUMULATED DEFICIT				TOTAL
Balance at January 1, 2022			33,009,000				3,301				4,926,879				(7,358,916	)			(2,428,736	)
Net loss			-				-				-				(233,120	)			(233,120	)
Balance at March 31, 2022			33,009,000				3,301				4,926,879				(7,592,036	)			(2,661,856	)
Balance at January 1, 2021			33,009,000				3,301				4,926,879				(6,711,352	)			(1,781,172	)
																			-
Net loss			-				-				-				(210,355	)			(210,355	)
																			-
Balance at March 31, 2021			33,009,000				3,301				4,926,879				(6,921,707	)			(1,991,527	)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4

 

 

BIO ESSENCE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2022 (UNAUDITED) AND DECEMBER 31, 2021

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Bio Essence Corporation (“the Company” or “Bio Essence”) was incorporated in 2000 in the state of California. Fusion Diet Systems (“FDS”) was incorporated in 2010 in the state of Utah. Bio Essence and FDS were under common control since 2016. Bio Essence and FDS are mainly engaged in manufacturing and distributing health supplement products. In January 2017, Bio Essence incorporated two subsidiaries in the state of California: Bio Essence Pharmaceutical Inc. (“BEP”) and Bio Essence Herbal Essentials, Inc. (“BEH”), Bio Essence transferred its manufacturing operation to BEP, and transferred its distributing operation to BEH. On March 1, 2017, the 100% shareholder of FDS transferred all of her ownership in FDS to Bio Essence. On December 7, 2021, the Company dissolved FDS. On November 12, 2021, Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in developing, manufacturing and sales of prescription medicine. As a result of the ownership restructure, BEP BEH and McBE became wholly owned subsidiaries of Bio Essence. McBE has not engaged any operations since its inception.

 

In December 2019, a novel strain of coronavirus, causing a disease referred to as COVID-19, was reported. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the pandemic has resulted in quarantines, travel restrictions, and the temporary closure of office buildings and facilities in the US. The state of California, where the Company is headquartered, has been affected by COVID-19. The global economy has also been materially negatively affected by COVID-19 and there is continued uncertainty about the duration and intensity of its impacts. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing the Company’s ability to access capital, which could negatively affect the Company’s liquidity.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Consolidation

 

The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation.

 

The interim consolidated financial information as of March 31, 2022 and for the three-month periods ended March 31 30, 2022 and 2021 was prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures, which are normally included in CFS prepared in accordance with U.S. GAAP were not included. The interim consolidated financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

 

In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present a fair statement of the Company’s consolidated financial position as of March 31, 2022, its consolidated results of operations and cash flows for the three months ended March 31, 2022 and 2021, as applicable, were made. The results for the period ended March 31, 2022 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2022 or for any future period.

 

Going Concern

 

The Company incurred net losses of $233,120 and $210,355 for the three months ended March 31, 2022 and 2021, respectively. The Company also had an accumulated deficit of $7,592,036 as of March 31, 2022. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

5

 

 

Leases 

 

The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s consolidated balance sheets.

 

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

The Company elected the package of practical expedients permitted under the transition guidance to combine the lease and non-lease components as a single lease component for operating leases associated with the Company’s office space lease, and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.

 

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. The Company recognized no impairment of ROU assets as of March31, 2022 and December 31, 2021. 

 

Cash and Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2022 and December 31, 2021, the bad debt allowance was $2,252 and $2,252, respectively.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value with cost determined on a weighted-average basis. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down their inventories to net realizable value, if lower.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets as follows: 

 

Leasehold improvements		7-10 years
Office furniture		5 years

 

6

 

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

 

Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of March 31, 2022 and December 31, 2021, there was no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets also include the prior years’ net operating losses carried forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income. 

 

At March 31, 2022 and December 31, 2021, the Company did not take any uncertain positions that would necessitate recording a tax related liability. The Company files a U.S. income tax return. With few exceptions, the Company’s U.S. income tax return filed for the years ending on December 31, 2019 and thereafter are subject to examination by the relevant taxing authorities.

 

7

 

 

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

 

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.

 

Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the manufactured goods were delivered to the customers.

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2022 and 2021.

 

Cost of Revenue

 

Cost of goods sold (“COGS”) consists primarily of finished goods purchased from other manufacturers, material costs, labor costs and related overhead that are directly attributable to the production of the products. Write-down of inventory to lower of cost or net realizable value is also recorded in COGS.

 

Cost of manufacture service consists primarily of direct labor costs and related overhead that are directly attributable to the manufacture process.

 

Shipping and Handling Costs

 

Shipping and handling costs related to delivery of finished goods are included in selling expenses. During the three months ended March 31, 2022 and 2021, shipping and handling costs were $9,340 and $8,134, respectively.

 

Advertising 

 

Advertising expenses consist primarily of costs of promotion and marketing for the Company’s image and products, and costs of direct advertising, and are included in selling expenses. The Company expenses all advertising costs as incurred. During the three months ended March 31, 2022 and 2021, advertising expense was $1,274 and $5,965, respectively.

 

Fair Value (“FV”) of Financial Instruments

 

Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

8

 

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:

 

●

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

●

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

●

Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.

 

As of March 31, 2022 and December 31, 2021, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV. The carrying value of cash, accounts receivable, prepaid expenses, advances to suppliers, accounts payable, taxes payable, other payables and accrued liabilities approximate estimated fair values because of their short maturities.

 

Share-based Compensation

 

The Company accounts for share-based compensation awards in accordance with ASC 718, “Compensation – Stock Compensation”. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date and amortized on a straight-line basis over the requisite service period or vesting period. The Company records forfeitures as they occur.

 

Earnings (Loss) per Share (EPS)

 

Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed similar to basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if all the potential common shares pertaining to warrants, stock options, and similar instruments had been issued and if the additional common shares were dilutive. Diluted EPS are based on the assumption that all dilutive convertible shares and stock options and warrants were converted or exercised. Dilution is computed by applying the treasury stock method for the outstanding unvested restricted stock, options and warrants, and the if-converted method for the outstanding convertible instruments. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later) and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, outstanding convertible instruments are assumed to be converted into common stock at the beginning of the period (or at the time of issuance, if later). There were no potentially dilutive securities outstanding (options and warrants) for the three months ended March 31, 2022 and 2021.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.

 

For the three months ended March 31, 2022, the company had one major customer accounted for 27% of the Company’s total sales. During the three months ended March 31, 2021, no customer accounted for more than 10% of the Company’s total sales.

 

The Company had four major vendors accounted for 23%, 19%, 10% and 10%, respectively, of total purchases during the three months ended March 31, 2022. The Company had four major vendors accounted for 30%, 24%, 11% and 10%, respectively, of total purchase during the three months ended March 31, 2021.

 

9

 

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. 

 

Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: manufacture and sale of health supplement products.

 

New Accounting Pronouncements

 

Recently issued accounting pronouncements not yet adopted

 

In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The guidance should be adopted on a prospective basis. As a smaller reporting company, the standard will be effective for the Company for interim and annual reporting periods beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of adopting this standard on its CFS.

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company is currently evaluating the impact that ASU 2020-06 may have on its CFS and related disclosures.

 

3. INVENTORY

 

Inventory consisted of the following at March 31, 2022 and December 31, 2021:

 

		March 31, 2022				December 31, 2021
		(unaudited)
Raw materials		$	73,826			$	49,706
Finished goods – health supplements			210,682				189,360
Less: Inventory impairment allowance			(26,097	)			(26,097	)
Total		$	258,412			$	212,969

 

10

 

 

4. SECURITY DEPOSIT

 

As of March 31, 2022 and December 31, 2021, the security deposit was for rent of the Company’s office and warehouse of $41,841.

 

5. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at March 31, 2022 and December 31, 2021:

 

		March 31, 2022				December 31, 2021
		(unaudited)
Leaseholder improvements		$	57,067			$	57,067
Office furniture and equipment			303,106				287,029
Total			360,173				344,096
Less: Accumulated depreciation			(174,002	)			(163,187	)
Net		$	186,171			$	180,909

 

Depreciation for the three months ended March 31, 2022 and 2021 was $10,815 and $5,836, respectively. 

 

6. INTANGIBLE ASSETS, NET

 

Intangible assets consisted of the following as of March 31, 2022 and December 31, 2021: 

 

		March 31, 2022				December 31, 2021
		(unaudited)
Computer Software		$	36,928			$	36,928
Trademark			2,350				2,350
Total			39,278				39,278
Less: Accumulated amortization			(38,299	)			(38,241	)
Net		$	979			$	1,037

 

Amortization of intangible assets was $6,349 and $10,716 for the three months ended March 31, 2022 and 2021, respectively. 

 

Estimated amortization for the existing intangible assets with finite lives for each of the next five years at March 31 , 2022 is as follows: $240, $240, $240, $240 and $3. 

 

7. TAXES PAYABLE

 

Taxes payable at March 31, 2022 and December 31, 2021 was for sales tax and payroll tax payable of $16,747 and $12,428, respectively. 

   

8. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following March 31, 2022 and December 31, 2021:

 

		March 31, 2022				December 31, 2021
		(unaudited)
Accrued expenses		$	3,852			$	9,686
Credit card payable			44,107				39,190
Customer deposit			56,850				28,283
Deferred income			1,042				-
Total		$	105,851			$	77,109

 

11

 

 

9. GOVERNMENT LOANS PAYABLE

 

In May and June 2020, BEH, BEP and FDS received a total of $127,740 from the Paycheck Protection Program loan (“PPP loan”) from US Small Business Administration (“the SBA”). The loan will be fully forgiven if the funds are used for payroll costs, interest on mortgages, rent, and utilities (at least 60% of the forgiven amount must have been used for payroll). The loan amount not forgiven, will have annual interest of 1%. Loan payments will be deferred to either (1) the date that SBA remits the borrower’s loan forgiveness amount to the lender or (2) if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness covered period. Loans issued prior to June 5, 2020 have a maturity of two years, loans issued after June 5, 2020 have a maturity of five years. No collateral or personal guarantees are required. A borrower may apply for loan forgiveness any time on or before the maturity date of the loan, including before the end of the Covered Period (either (1) the 24-week (168-day) period beginning on the PPP Loan Disbursement Date, or (2) if the Borrower received its PPP loan before June 5, 2020, the Borrower may elect to use an eight-week (56-day) Covered Period); provided such application for loan forgiveness is made within 10 months after the last day of the covered period, otherwise the loan is no longer deferred and the borrower must begin paying principal and interest. Subsequently, The U.S. Treasury and SBA announced a streamlined PPP forgiveness application for loans of $50,000 or less (unless those borrowers together with their affiliates received loans totaling $2 million or more). It requires fewer calculations and may call for less documentation. It does not require borrowers to reduce their loan forgiveness calculations if they have reduced full-time equivalent (“FTE”) or salaries. In addition, in February 2021, BEH, BEP and FDS received a total of $115,245 from the second round of PPP loan from the SBA. As of December 31, 2021, all BEH, BEP and FDS’ PPP loans’ forgiveness were approved and the Company recorded $242,985 PPP loan forgiveness as other income in the year ended December 31, 2021.

  

In May and June 2020, BEH, BEP and FDS received total of $215,600 from the Economic Injury Disaster Loan (“EIDL loan”) from the SBA after deducting $100 Uniform Commercial Code (“UCC”) handling charge and filing fee for each company. This is a low-interest federal disaster loan for working capital to small businesses and non-profit organizations of any size suffering substantial economic injury as a result of the Coronavirus (COVID-19), to help the businesses to meet financial obligations and operating expenses that could have been met had the disaster not occurred. This loan has interest of 3.75% and is not forgivable. The maturity of the loan is 30 years, installment payments including principal and interest of $515 monthly will begin 12 months from the date of the promissory note. On March 4, 2022, The FDS transferred its EIDL loan to BEC due to the dissolution of FDS.

 

As of March 31, 2022, the future minimum loan payments (including the PPP loan and EIDL loan) to be paid by year are as follows:

 

Year Ending		Amount
		(unaudited)
March31, 2023		$	4,469
March31, 2024			4,639
March31, 2025			4,816
March31, 2026			5,000
March31, 2027			5,191
Thereafter			191,485
Total		$	215,600

 

10. RELATED PARTY TRANSACTIONS

 

Loans from Shareholder

 

At March 31, 2022 and December 31, 2021, the Company had loans from one major shareholder (also the Company’s senior officer) for $2,035,155 and $1,785,154, respectively. At March 31, 2022 and December 31, 2021, the Company had loan from another major shareholder for $608,631 for settling the litigation There are no written loan agreements for these loans. These loans are unsecured, non-interest bearing and have no fixed terms of repayment, and therefore, deemed payable on demand. Cash flows from loans form shareholder are classified as cash flows from financing activities. 

 

11. INCOME TAXES

 

The Company and its subsidiaries are subject to 21% federal corporate income tax in US.

 

At March 31, 2022 and December 31, 2021, the Company had net operating loss (“NOL”) for income tax purposes; for federal income tax purposes, the NOL arising in tax years beginning after 2017 may only reduce 80% of a taxpayer’s taxable income, and may be carried forward indefinitely; for California income tax purposes, the entire NOL can be carried forward up to 20 years. However, the coronavirus Aid, Relief and Economic Security Act (“the CARES Act”) issued in March 2020, provides tax relief to both corporate and noncorporate taxpayers by adding a five-year carryback period and temporarily repealing the 80% limitation for NOLs arising in 2018, 2019 and 2020.

 

12

 

 

The Company has NOL carry-forwards for Federal and California income tax purposes of $4.44 million and $4.22 million at March 31, 2022 and December 31, 2021, respectively. No tax benefit was reported with respect to these NOL carry-forwards in the accompanying consolidated financial statements because the Company believes the realization of the Company’s net deferred tax assets for the NOL for both federal and California State of approximately $1.24 million as of March 31, 2022, was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are fully offset by a full valuation allowance.

  

Components of the Company’s deferred tax assets as of March 31, 2022 and December 31, 2021 are as follows:

 

		March 31, 2022				December 31, 2021
		(unaudited)
Net deferred tax assets:
Bad debt expense		$	1,978			$	1,978
Inventory impairment (reversal)			697				697
Operating lease charge			14,844				14,821
Depreciation and amortization			(2,561	)			(2,561	)
Expected income tax benefit from NOL carry-forwards			1,243,701				1,181,525
Less: valuation allowance			(1,258,659	)			(1,196,460	)
Deferred tax assets, net of valuation allowance		$	-			$	-

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the consolidated federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes for the three months ended March 31, 2022 and 2021 is as follows:

 

		2022				2021
		(unaudited)
Federal statutory income tax expense (benefit) rate			(21.00	)%			(21.00	)%
State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax			(6.98	)%			(5.39	)%
Change in valuation allowance			27.98	%			24.8	%
Effective income tax rate			-	%			1.59	%

 

The provision for income tax expense for the three months ended March31, 2022 and 2021 consisted of the following:

 

		2022				2021
		(unaudited)
Income tax expense – current		$	-			$	3,300
Income tax benefit – current			-				-
Total income tax expense		$	-			$	3,300

  

12. LEASES

 

Operating Leases

 

Warehouse and office lease

 

Effective October 1, 2018, the Company entered a 62.5 months lease for a facility including warehouse and office in the City of Irvine, California, with a security deposit of $41,841. The monthly rent is approximately $16,200 with a 3% increase each year. The lease provided an option to extend at lease maturity for another five-years, with six months prior written notice of lessee’s intention to extend the lease. The Company’s CEO is the guarantor of this lease. Lessor will have the right to proceed against guarantor following any breach or default by lessee without first proceeding against lessee and without previous notice to or demand upon either lessee or guarantor.

 

13

 

 

The components of lease costs, lease term and discount rate with respect of warehouse and office lease in the City of Irvine with an initial term of more than 12 months are as follows:

 

		Three Months Ended March 31, 2022				Three Months Ended March 31, 2021
Operating lease cost		$	53,281			$	53,281
Weighted Average Remaining Lease Term - Operating leases including options to renew			6.51 years				7.51 years
Weighted Average Discount Rate - Operating leases			5	%			5	%

 

The following is a schedule, by years, of maturities of warehouse and office lease liabilities as of March 31, 2022:

 

For the 12 months ending		Operating Leases
March 31, 2023		$	217,585
March 31, 2024			224,113
March 31, 2025			225,757
March 31, 2026			225,757
March 31, 2027			225,757
Thereafter			338,635
Total undiscounted cash flows			1,457,603
Less: imputed interest			(216,514	)
Present value of lease liabilities		$	1,241,088

 

Equipment leases

 

In 2017, the Company entered two leases for two copiers with terms of 60 and 63 months respectively, and monthly payments of $162 and $213, respectively. The Company also entered two leases for two forklifts with a term of 60 months for each, and the monthly payment was $292 and $669, respectively.

 

The components of lease costs, lease term and discount rate with respect of equipment lease with an initial term of more than 12 months are as follows:

 

		Three Months Ended				Three Months Ended
		March 31, 2022				March 31, 2021
Operating lease cost		$	4,008			$	4,030
Weighted Average Remaining Lease Term - Operating leases			0.19 years				1.19 years
Weighted Average Discount Rate - Operating leases			5	%			5	%

 

The following is a schedule, by years, of maturities of lease liabilities as of March31, 2022:

 

For the 12 months ending		Operating Leases
March 31, 2022		$	2,254
Total undiscounted cash flows			2,254
Less: imputed interest			(28	)
Present value of lease liabilities		$	2,226

 

Finance lease

 

Effective March 15, 2022, the Company entered two 39-months lease for two copiers with same vendor for a monthly payment of $234 and $214, respectively. At the lease expiration date, the Company has the option to purchase the copier for $1 each.

 

14

 

 

The components of lease costs, lease term and discount rate with respect of the copier lease with an initial term of more than 12 months are as follows:

 

		Three Months Ended March 31, 2022
Finance lease cost		$	-
Weighted Average Remaining Lease Term - Finance leases			3.25
Weighted Average Discount Rate – Finance leases			5	%

 

The following is a schedule, by years, of maturities of finance lease liabilities as of March 31, 2022:

 

For the 12 months ending		Finance Leases
March 31, 2023		$	5,370
March 31, 2024			5,370
March 31, 2025			5,370
March 31, 2026			1,343
Total undiscounted cash flows			17,452
Less: imputed interest			(1,375	)
Present value of finance lease liabilities		$	16,077

 

13. LOAN PAYABLES

 

In June 2021, the Company entered a loan agreement of $14,549 for purchasing a Videojet with interest rate of 14.11% and a term of three-years. In September 2021, the Company entered another loan agreement of $39,218 for purchasing a spectrophotometer workstation with interest rate of 10.26% and a term of five-years. The Company recorded interest expense of $1,345 during the three months ended March 31, 2022.

 

The following is a schedule, by years, of maturities of loan payable as of March 31, 2022:

 

For the 12 months ending		Loan Payable
March 31, 2023		$	15,882
March 31, 2024			10,958
March 31, 2025			9.974
March 31, 2026			4,156
Total undiscounted cash flows			56,853
Less: imputed interest			(10,578	)
Present value of loan payable		$	46,275

 

14. SUBSEQUENT EVENTS

 

The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company did not have any material subsequent event.

 

15

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Business Overview

 

Bio Essence Corporation (“the Company” or “Bio Essence”) was incorporated in 2000 in the state of California. Fusion Diet Systems (“FDS”) was incorporated in 2010 in the state of Utah. Bio Essence and FDS were owned under common control since 2016. Bio Essence and FDS are mainly engaged in manufacturing and distributing health supplement products. In January 2017, Bio Essence incorporated two subsidiaries in the state of California: BEP and BEH, Bio Essence transferred its manufacturing operation into BEP, and transferred its distributing operation into BEH. On March 1, 2017, the 100% shareholder of FDS transferred all her ownership in FDS into Bio Essence. On December 7, 2021, the Company dissolved FDS. On November 12, 2021, Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in research and development and manufacture of prescription medicine. As a result of the ownership restructure, BEP, BEH, and MCBE became wholly owned subsidiaries of Bio Essence, and Bio Essence serves as a holding corporation for these subsidiaries. McBE has not engaged any operations since its inception.

 

The primary focus of BEP is producing products for BEH, along with providing OEM services to other companies. BEH targets healthcare practitioners with herbal products in the form of granules, capsules, pills and tablets. It also offers special formulation service to practitioners. The Company intends to develop the subsidiary into an integrated healthcare platform that provides customers direct connections with integrative healthcare practitioners such as dietitians, nutraceutical practitioners, and other practitioners in this discipline worldwide.

 

However, the pandemic could result in significant disruption of global financial markets, reducing the Company’s ability to access capital, which could negatively affect the Company’s liquidity.

  

Related Party Transactions

 

Loans from Officer

 

At March 31, 2022 and December 31, 2021, the Company had loans from one major shareholder (also the Company’s senior officer) of $2,035,155 and $1,785,154, respectively. At March 31, 2022 and December 31, 2021, the Company had loan from another major shareholder for $608,631 for settling the litigation (see Note 8). There are no written loan agreements for these loans. These loans are unsecured, non-interest bearing and have no fixed terms of repayment, and therefore, deemed payable on demand.

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements (“CFS”), which were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported net sales and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

  

While our significant accounting policies are more fully described in Note 2 to our CFS, we believe the following accounting policies are the most critical to assist you in fully understanding and evaluating this management discussion and analysis.

 

Basis of Presentation

 

The accompanying consolidated financial statements (“CFS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”). The consolidated financial statements include the financial statements of the Company and its subsidiaries, BEP, BEH and McBE. All significant inter-company transactions and balances were eliminated in consolidation. 

 

16

 

 

Going Concern

 

The Company incurred net losses of $233,120 and $210,355 for the three months ended March 31, 2022 and 2021, respectively. The Company also had an accumulated deficit of $7,592,036 as of March 31, 2022. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. 

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2022 and December 31, 2021, the bad debt allowance was $2,252 and $2,252, respectively.

 

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

  

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.

 

Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the finished goods were delivered to the customers.

 

17

 

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the three months ended March 31, 2022 and 2021.

 

Results of operations

 

Comparison of three months ended March 31, 2022 and 2021

 

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales. Certain columns may not add due to rounding.

 

		2022				% of Sales				2021				% of Sales				Dollar Increase (Decrease)				Percent Increase (Decrease)
Sales of goods		$	181,579				59.26	%		$	212,028				100	%		$	(30,449	)			(14.36	)%
Manufacture service revenue			124,835				40.74	%			-				-	%			124,835				-	%
Total revenues			306,414				100	%			212,028				100	%			94,386				44.52	%
Sales of goods cost			145,665				80.22	%			135,309				63.82	%			10,356				7.65	%
Cost of manufacture service			90,293				72.33	%			-				-	%			90,293				-	%
Total cost of revenues			235,958				77.01	%			135,309				63.82	%			100,649				74.38	%
Gross profit			70,456				22.99	%			76,179				36.18	%			(6,263	)			(8.16	)%
Selling expenses			10,614				3.46	%			15,523				7.32	%			(4,909	)			(31.62	)%
Bad debts			-				-	%			380				0.18	%			(380	)			(100	)%
General and administrative expenses			286,274				93.43	%			265,347				125.15	%			20,927				7.89	%
Operating expenses			296,888				96.89	%			281,250				132.65	%			15,638				5.56	%
Loss from operations			(226,432	)			(73.9	)%			(204,531	)			(96.46	)%			(21,901	)			10.71	%
Other income (expense), net			(6,688	)			(2.18	)%			(2,524	)			(1.19	)%			(4,164	)			164.98	%
Loss before income taxes			(233,120	)			(76.08	)%			(207,055	)			(97.65	)%			(26,065	)			12.59	%
Income tax expense			-				-	%			3,300				1.56	%			(3,300	)			(100	)%
Net loss		$	(233,120	)			(76.08	)%		$	(210,355	)			(99.21	)%		$	(22,765	)			10.82	%

 

Sales

 

Sales for the three months ended March 31, 2022 and 2021 were $306,414 and $212,028, respectively, an increase of $94,386 or 44.52%. The increase was primarily attributable to (i) increase the big purchase orders from new customers, (ii) increased revenue from manufacture service (OEM) provided by BEP, and (iii) purchased of new equipment to enhance our ability to complete and deliver the big orders in a more speedy and efficient way.

  

Costs of sales

 

Costs of sales for the three months ended March 31, 2022 and 2021 was $235,958 and $135,309, respectively, an increase of $100,649 or 74.38%. The increase of COGS in 2022 was due to increased revenue and increased cost of production especially the labor. During the three months ended March 31, 2022, we received quite a few big orders especially the OEM orders, which required more manufacture labors to complete the orders. In addition, we had inventory adjustment for obsolete inventory of $41,854 during the three months ended March 31, 2022. The percentage of cost of sales of goods to total sales of goods was 80.22% and 63.82% for the three months ended March 31, 2022 and 2021, respectively. The percentage of cost of manufacture services to total manufacture income was 72.33% and 0.00% for the three months ended March 31, 2022 and 2021, respectively.

 

18

 

 

Gross profit

 

The gross profit for the three months ended March 31, 2022 and 2021 was $70,456 and $76,719, respectively, a decrease of $6,263 or 8.16%. The blended profit margin was 23.0% and 36.2% for the three months ended March 31, 2022 and 2021, respectively.

 

Operating expenses

 

Selling expenses consist mainly of advertising, show expense, products marketing, shipping expenses, and promotion expenses. Selling expense was $10,614 for the three months ended March 31, 2022, compared to $15,523 for the three months ended March 31, 2021, a decrease of $4,909 or 31.62%, mainly resulting from decreased advertising expense by $5,960, was partly offset by increased shipping expense by $1,200.

 

Bad debt expense was $0 for the three months ended March 31, 2022, compared to $380 for the three months ended March 31, 2021, a decrease of $380 or 100%.

 

General and administrative expenses consist mainly of employee salaries and welfare, business meeting, utilities, accounting, consulting, and legal expenses. General and administrative expenses were $286,274 for the three months ended March 31, 2022, compared to $265,347 for the three months ended March 31, 2021, an increase of $20,927 or 7.89%, the increase was mainly due to increased salaries expense by $46,650, was partly offset by decreased consulting fee by $17,200, and decreased other G&A expenses by $8,520.

 

Other expenses, net

 

Other expenses was $6,688 and $2,524 for the three months ended March 31, 2022 and 2021, respectively. For the three months ended March 31, 2022, other expenses mainly consisted of interest expense of $5,160, financial expense of $1,568 and other income of $40. For the three months ended March 31, 2021, other expenses mainly consisted of interest expense of $2,763, financial expense of $3,299 and other income of $3,538.

 

Net loss

 

We had a net loss of $233,120 for the three months ended March 31, 2022, compared to $210,355 for the three months ended March 31, 2021, an increase of $22,765 or 10.82%, reflected the above-mentioned factors combined.

  

Liquidity and Capital Resources

 

As of March 31, 2022, we had cash and equivalents of $225, bank overdraft of 27,400, other current assets of $378,638, other current liabilities (excluding bank overdraft) of $3,074,991, working capital deficit of $2,723,528, a current ratio of 0.12:1. As of December 31, 2021, we had cash and equivalents of $303, bank overdraft of $19,032, other current assets of $261,659, other current liabilities (excluding bank overdraft) of $2,736,932, working capital deficit of $2,494,002, a current ratio of 0.10:1. The following is a summary of cash provided by or used in each of the indicated types of activities during the three months ended March 31, 2022, and 2021, respectively.

 

		2022				2021
Net cash used in operating activities		$	(254,475	)		$	(158,639	)
Net cash used in investing activities		$	-			$	(6,837	)
Net cash provided by financing activities		$	254,397			$	170,409

 

Net cash used in operating activities

 

Net cash used in operating activities was $254,475 for the three months ended March 31, 2022, compared to $158,639 in 2021. The increase of cash outflow of $95,836 from operating activities for the three months ended March 31, 2022 was principally attributable to increased cash outflow on accounts receivable by $57,974 and increase cash outflow on inventory by $40,093.

 

19

 

 

Net cash used in investing activities

 

Net cash used in investing activities was $0 for the three months ended March 31, 2022, compared to $6,837 in 2021. We did not have any investing activities for the three months ended March 31, 2022; for the three months ended March 31, 2021, we purchased fixed assets of $9,537, but offset with the proceeds from sale of fixed assets for $2,700.

 

Net cash provided by financing activities

 

Net cash provided by financing activities was $254,397 for the three months ended March 31, 2022, compared to $170,409 in 2021. The net cash provided by financing activities for the three months ended March 31, 2022 consisted of proceeds of $250,000 from loans from one major shareholder (also the senior officer), but partly offset by repayment of loan payable of $3,970. The net cash provided by financing activities for three months ended March 31, 2021 mainly consisted of proceeds from government loans of $115,245 due to the Covid-19, and loan from a major shareholder (also the senior officer) of $84,146, but partly offset by bank overdraft of $28,982. 

 

Our current liabilities exceed current assets at March 31, 2022, and we incurred substantial losses and cash outflows from operating activities in the periods presented. We may have difficulty to meet upcoming cash requirements. As of March 31, 2022, our principal source of funds was loans from an officer (also is the Company’s major shareholder). As of March 31, 2022, we believe we will need $1.2 million cash to continue our current business for the next 12 months. In addition to our continuous effort to improve our sales and net profits, we have explored and continue to explore other options to provide additional financing to fund future operations as well as other possible courses of action. Such actions may include, but are not limited to, securing lines of credit, sales of debt or equity securities (which may result in dilution to existing shareholders), loans and cash advances from other third parties or banks, and other similar actions. There can be no assurance that we will be able to obtain additional funding (if needed), on acceptable terms or at all, through a sale of our common stock, loans from financial institutions, or other third parties, or any of the actions discussed above. If we cannot sustain profitable operations, and additional capital is unavailable, lack of liquidity could have a material adverse effect on our business viability, financial position, results of operations and cash flows.

 

Off-Balance Sheet Arrangements

 

We have not entered into any financial guarantees or other commitments to guarantee the obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, as defined in 17 CFR § 229.10(f)(1), we are not required to provide the information requested by this Item.

 

Item 4. Controls and Procedures.

 

The Company’s Chief Executive, Yin Yan, is responsible for establishing and maintaining disclosure controls and procedures for the Company.

 

Evaluation of Disclosure Controls and Procedures

 

For purposes of this Item 4, the term disclosure controls and procedures means controls and other procedures of the Company (i) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (15 U.S.C. 78a et seq. and hereinafter the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and (ii) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

20

 

 

On March 31, 2022, Ms. Yan reviewed the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report and has concluded that the Company’s disclosure controls and procedures are effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC.

 

Report of Management

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”), as defined in Exchange Act Rule 13a-15. Our ICFR is designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. Management conducted an assessment of our ICFR based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on the assessment, management concluded that, as of March 31, 2022, our ICFR were effective at the reasonable assurance level based on those criteria.

 

Our independent public accountant has not conducted an audit of our controls and procedures regarding ICFR and therefore expresses no opinion with regards to the effectiveness or implementation of our controls and procedures with regards to ICFR.

 

Changes in Internal Controls over Financial Reporting

 

There were no changes in our ICFR identified in connection with our evaluation of these controls as of the end of the quarter ending on March 31, 2022 as covered by this report that has materially affected, or is reasonably likely to materially affect, our ICFR.

 

Inherent Limitations on Effectiveness of Controls 

 

The Company’s management does not expect that its disclosure controls or its ICFR will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ending on March 31, 2022 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

 

21

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

There have been no unregistered sales of equity securities in the first quarter of 2022.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Not applicable.

 

22

 

 

Item 6. Exhibits.

 

Incorporated by reference

Exhibit

Exhibit Description

Filed herewith

Form

Period ending

Exhibit

Filing date

31.1

Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

X

32.1

Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

X

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Link base Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

23

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

BIO ESSENCE CORP.
/s/ Yin Yan
By: Yin Yan
Its: Chairman of the Board, Chief
Executive Officer, Chief Financial Officer
Date: May 16, 2022

 

 

24